Targeted Proteomic Biomarker Profiling Using NULISA in a cohort enriched with risk for Alzheimer’s Disease and Related Dementias

Competing Interest Statement

HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). BBB has consulted for New Amsterdam Pharma, Cognito Therapeutics, Merry Life Biomedical, and is co-founder of Cognovance (outside submitted work). SCJ has served on scientific advisory boards for ALZPath and Enigma Biomedical. BBB has consulted for New Amsterdam Pharma, Cognito Therapeutics, Merry Life Biomedical, and is co-founder of Cognovance (outside submitted work). NAC has done consulting for New Amsterdam Pharm. The following authors reported no financial or non-financial disclosures: Ramiro Eduardo Rea Reyes, Rachael E. Wilson, Rebecca E. Langhough, Rachel L. Studer, Erin M. Jonaitis, Julie E. Oomens, Elizabeth M. Planalp, and Sanjay Asthana.

Funding Statement

The authors would like to acknowledge the National Institute of Health (NIH) for their support under the following grants P30 AG062715, R01 AG027161, R01 AG021155. Additionally, they would like to acknowledge the Wisconsin Alzheimer's Disease Research Center, and the Alzheimer's Association Research Foundation (AARF) for financial support of this work. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study procedures received approval from the University of Wisconsin-Madison Institutional Review Board and were conducted in compliance with the World Medical Association Declaration of Helsinki. All subjects provided informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes